Beranda › Penyakit Paru Interstisial › South Carolina
Uji klinis Penyakit Paru Interstisial di South Carolina
14 studi untuk Penyakit Paru Interstisial mencari peserta di lokasi di South Carolina.
Kota di South Carolina
Teks studi resmi (Bahasa Inggris)
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Lowcountry Lung and Critical Care, Charleston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Medical University of South Carolina, Charleston
Menerima pesertaFase 3
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07201922LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- MUSC, Charleston
- Velocity Clinical Research, Spartanburg
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05798923SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
- Medical University of South Carolina, Charleston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07269262A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Medical University of South Carolina, Charleston
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06968845A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Charleston
Menerima pesertaFase 2
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07333183Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Medical University of South Carolina, Charleston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- AnMed Health, Anderson
- Medical University of South Carolina, Charleston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Medical University of South Carolina (MUSC), Charleston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06195072Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Medical University of South Carolina, Charleston
Menerima pesertaStudi observasional
Usia 21 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT01915511Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Medical University of South Carolina-Nexus, Charleston
- Prisma Health Pulmonology-Richland, Columbia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05943535An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Medical University of South Carolina, Charleston
Menerima pesertaStudi observasional
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT06129240Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- Bogan Sleep Consultants, LLC, Columbia
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT05975983Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Charleston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mei 2025 · NCT05892614Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.